BioSpace News Archive

Beginning this week, plasma from whole blood and platelet donations made through the American Red Cross that test positive for COVID-19 antibodies may now help coronavirus patients in need of convalescent plasma transfusions.

Nutcracker Therapeutics, Inc., a company developing and producing mRNA therapeutics on its proprietary, microfluidic, biochip-based platform, today announced the appointment of Madhavan (“Madhu”) Balachandran, former executive vice president of operations at Amgen, as chief operating officer. Balachandran will oversee all op

Whether children have returned to in-school classrooms, are learning remotely at home, or are doing a combination of both, the 2020-2021 school year promises to be a constantly changing and challenging experience during the ongoing pandemic.

Novian Health Inc., a pioneer in destroying breast tumors with laser treatments, announced that it has been selected by as one of 50 companies in MedTech Innovator’s flagship four-month Showcase and Accelerator program.

Spinal Elements, a Carlsbad, CA-based medical device company focused on spine surgery procedures, today announced a senior leadership appointment to support its continuing growth. Rick Simmons joined Spinal Elements as Chief Marketing Officer with responsibility for Marketing, Product Development and Business Development, effective August 3, 2020. Simmons brings to Spinal Elements over 30 years of commercial experience

Stella Diagnostics, Inc . (OTC Markets: JMDP), a molecular diagnostics-based organization focused on improving patient management strategies for over 67 million people living with severe esophageal disease, announced today that it was selected as the Buzz of BIO winner for the 2020 BIO Investor Forum Digital in the ‘Diagnostics and Beyond’ category. Stella Diagnostics also received an invitation to deliver a podium presenta

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the launch of its “Forward for Health Equity” grant program.

Company is usi n g its Artificial Immune Modulation (AIM) nanoparticle technology to develop T cell immunotherapies for p atients with relapsed and/or refractory hematologic malignancies GAITHERSBURG, Md., Sept. 23, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunotherapies, announced today that it has completed dosing of the first safety cohort (n=3) in its Phase 1/2 clinical trial for NEXI-

Centene Corporation announced that it has commenced an underwritten public offering to sell $2,200,000,000 of senior notes due 2030, subject to market and other conditions.

Metabolon, Inc., the global leader in metabolomics solutions advancing drug development and precision medicine, today announced the close on $72 million in combined debt and equity financing.